Slide(s) - Programme général Tours 2007 |
16:00 | 17:30 - Characterization of antibodies to red cells prepared with S-303 pathogen inactivation treatment with resumption of clinical trials
Laurence CORASH, Cerus Corporation, Concord, CA, Etats-Unis
|